Skip to content
Peptide research

Pancragen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A synthetic tetrapeptide marketed to support pancreatic function and blood sugar control in aging adults. Human evidence is weak, limited to small elderly-diabetic studies showing modest glucose drops, while cell-regeneration claims rest on animal and mechanism-only research. Safety data is minimal, and combining it with diabetes drugs risks hypoglycemia. Supply is mostly unregulated research-grade product, and it is not an approved drug in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Pancragen is a synthetic four-amino-acid peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of a 40-year Russian research program on short peptides that target specific organs. It was originally derived from bovine pancreatic tissue and is designed to support the health and function of the pancreas — both its insulin-producing beta cells and its digestive enzyme-producing cells. It is marketed as a dietary supplement in Russia and internationally, not as a pharmaceutical drug.

How it works in the body

A tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that targets pancreatic cells. It interacts with gene regulatory regions in beta cells and acinar cells to normalize insulin secretion, digestive enzyme production, and the overall functional capacity of pancreatic tissue.

Research overview

Pancragen works at the genetic level by entering cells, binding directly to DNA, and switching on the master genes that control pancreatic cell identity and insulin production (including PDX1, PAX6, and FOXA2). It also promotes favorable changes in how DNA is packaged (epigenetic modifications), effectively helping aged pancreatic cells behave more like younger ones. In studies on aged rhesus monkeys, a 10-day course of Pancragen normalized insulin dynamics, improved the rate at which glucose was cleared from the blood, and corrected impaired glucose tolerance — with effects lasting 3 weeks after the last dose. A human study in 33 elderly patients with type 2 diabetes showed significant reductions in fasting blood sugar, improved glucose tolerance, and decreased insulin resistance. The evidence base includes about 8-12 published papers spanning cell cultures, rodents, primates, and humans, but all originate from a single research group, sample sizes are small, and no independent replication exists outside of Russia.

Who researches Pancragen?

Commonly researched by

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Limited safety data and lack of independent validation

    High

    Single-school journal provenance of all cited PMIDs; no registered Pancragen/KEDW trial; no FDA approval

  • Hypoglycemia risk when combined with diabetes medications

    Moderate

    PMID 18642713; PMID 28509500 (fasting glucose reduction in old monkeys); PMID 22448364

  • Unregulated product quality (research-grade sources)

    High

    Regulatory status: not an FDA-approved drug; no USP monograph

  • Individual intolerance or allergic reaction

    Low

    No adverse events reported in published KEDW literature (e.g. PMIDs 22448364, 28509500)

  • Contraindicated in pregnancy and lactation

    Moderate

    PMID 25761685 (PDX1/PAX6/NGN3 as KEDW-responsive developmental gene targets); no reproductive toxicology published

Interaction summary(8)

Rated by direction with this peptide

  • Sulfonylureas (glimepiride, glipizide, glyburide)

    CautionModerate

    Both lower glucose, and pancragen was compared head-to-head with glimepiride in 9 old rhesus monkeys, where both agents reduced fasting glucose. Co-administration therefore risks additive hypoglycemia, particularly in elderly patients with blunted counter-regulation. No human co-administration data exists.

    PMID 28509500

  • Insulin

    CautionModerate

    Pancragen partially restored endogenous insulin synthesis in alloxan-diabetic rats and lowered fasting insulin and glucose in the elderly human series, so exogenous insulin doses may need downward adjustment to avoid hypoglycemia. Inferred from separate studies; no combination study exists.

    PMID 16671579; PMID 22448364

  • Metformin and other non-secretagogue oral antidiabetics

    CautionTheoretical

    Mechanisms are complementary — metformin acts on hepatic glucose output and peripheral sensitivity while pancragen appears to act on beta-cell function and the insulin resistance index — but no combination study has ever been performed. Additive glucose-lowering is possible, and there is no evidence the combination is beneficial, so treat this as an untested overlap rather than a demonstrated synergy.

    PMID 22448364 (insulin resistance index reduction); no combination data

  • GLP-1 receptor agonists and DPP-4 inhibitors

    CautionTheoretical

    Both classes enhance glucose-dependent insulin secretion, and using them with a peptide that normalized insulin and C-peptide dynamics in old monkeys could compound glucose-lowering. No interaction study exists.

    PMID 25946840 (insulin/C-peptide normalization); no interaction data

  • Systemic corticosteroids (prednisone, dexamethasone)

    CautionLow

    Steroid-induced insulin resistance and hyperglycemia would be expected to blunt or offset pancragen's glucose-lowering effect, so apparent loss of efficacy during a steroid course should not be read as tolerance. This is an efficacy-direction note, not an additive-harm signal.

    Mechanistic inference from established steroid hyperglycemia; no KEDW-specific data

  • Non-selective beta-blockers (propranolol)

    CautionTheoretical

    These mask the adrenergic warning signs of hypoglycemia, which raises the consequence — not the probability — of any glucose-lowering effect from pancragen in a treated diabetic.

    Mechanistic; established beta-blocker hypoglycemia-masking interaction; no KEDW-specific data

  • Alcohol

    CautionLow

    Alcohol suppresses hepatic gluconeogenesis and can deepen fasting hypoglycemia, compounding the consequence of any glucose-lowering agent; heavy use is also independently harmful to the pancreas. No KEDW-specific data.

    Mechanistic; established alcohol-induced hypoglycemia; no KEDW-specific data

  • Other Khavinson-school peptide bioregulators (e.g. Vesugen, Cortagen, Thymogen)

    NeutralTheoretical

    These tetrapeptides are reported by the originating group to act tissue-specifically on distinct gene sets, so no pharmacological interaction is predicted — but that tissue-specificity claim is itself unreplicated, and using several of them together has never been studied for safety.

    PMID 22808515; PMID 31808038 (review)

Known risks(5)

  • Limited safety data and lack of independent validation

    Moderate

    All safety data originates from a single research group (Khavinson et al.) with small sample sizes. No independent safety monitoring, pharmacovigilance, or large-scale safety trials have been conducted. No FDA review of safety has occurred. The absence of adverse events in published studies may reflect small sample sizes rather than true absence of risk.

  • Hypoglycemia risk when combined with diabetes medications

    Moderate

    Pancragen has demonstrated hypoglycemic effects in both animal models and human diabetic patients. Combining it with insulin, sulfonylureas (e.g., glimepiride), or other glucose-lowering agents could theoretically potentiate hypoglycemia. The manufacturer recommends use 'under the control of blood glucose' for patients with type 2 diabetes.

  • Unregulated product quality (research-grade sources)

    Moderate

    Unregulated Pancragen products sold online are not manufactured under pharmaceutical GMP standards and is not subject to FDA quality oversight. Purity, identity, and sterility may vary among unregulated products sold online. Contamination or incorrect peptide sequences are potential concerns with research-grade products.

  • Individual intolerance or allergic reaction

    Low

    The manufacturer lists individual intolerance to components as a contraindication. Capsule formulations contain inactive ingredients (microcrystalline cellulose, beet root sugar, lactose, starch, Tween-80) that may cause reactions in sensitive individuals. Lactose-intolerant individuals should note the lactose content.

  • Contraindicated in pregnancy and lactation

    Low (specific population)

    The manufacturer explicitly lists pregnancy and lactation as contraindications. No reproductive or developmental toxicity studies have been published.

Drug interactions(5)

  • Insulin and insulin analogs

    Pancragen has demonstrated hypoglycemic effects in animal models and human diabetic patients. Co-administration with exogenous insulin could potentiate hypoglycemia. Blood glucose should be closely monitored if Pancragen is used alongside insulin therapy.

  • Sulfonylureas (glimepiride, glipizide, glyburide)

    The comparative primate study (Goncharova et al. 2015) directly compared Pancragen to glimepiride. Both reduced blood glucose, and combining them could increase hypoglycemia risk. Concurrent use has not been studied and should be approached with caution.

  • Other oral hypoglycemic agents (metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists)

    Theoretical additive hypoglycemic effect. No interaction studies have been conducted. Patients on any glucose-lowering medication should monitor blood glucose carefully if adding Pancragen and consult their physician.

  • Other Khavinson peptide bioregulators

    No adverse interactions have been reported between Pancragen and other Khavinson bioregulators (e.g., Endoluten for pineal gland, Vladonix for thymus), though formal interaction studies have not been conducted.

  • Immunosuppressants

    Pancragen modulates immune-related markers (TNF-alpha, IGF-I, CD79a). Theoretical interaction with immunosuppressive therapy has not been studied. Caution is warranted in transplant patients or those on immunosuppressive regimens.

Research & benefits

Evidence base

Evidence Level
Limited Evidence
Total Studies
8

The clinical evidence for Pancragen is limited but internally consistent. The strongest human evidence comes from a single clinical study (Korkushko et al. 2011) in 63 elderly subjects showing that Pancragen significantly reduced fasting glucose, improved glucose tolerance, and lowered insulin resistance in type 2 diabetic patients. This was not a randomized, double-blind, placebo-controlled trial by modern Western standards. Two non-human primate studies in aged rhesus monkeys (Goncharova et al. 2014, 2015) provide the strongest preclinical evidence, demonstrating normalization of insulin dynamics and glucose tolerance with effects persisting after treatment cessation. In vitro studies confirm molecular mechanisms (gene expression modulation, epigenetic remodeling). The major limitations are: single research group origin, small sample sizes, lack of independent replication, and absence of formal clinical development outside Russia.

Researched for(5)

Rated by confidence in the evidence

  • Correction of impaired glucose tolerance in aging

    Low

    Metabolic effects were reported in aged monkeys and small human studies; independent confirmation was not identified in the reviewed evidence.

    PMID 25946840 (glucose disappearance rate, 3-week persistence); PMID 28509500 (pancragen vs glimepiride, n=9); PMID 22448364 (elderly human series)

  • Reduction of fasting glucose and insulin resistance in elderly diabetic patients

    Low

    Small human reports suggest glucose-lowering effects; robust independent confirmation was not identified in the reviewed evidence.

    PMID 22448364

  • Stimulation of pancreatic cell differentiation and anti-aging gene expression

    Low

    Consistent cell-culture data from one lab group, mechanism-supported, no independent confirmation.

    PMID 23486591; PMID 25761685; PMID 22808515; PMID 24770759

  • Hypoglycemic and endothelioprotective effects in experimental diabetes

    Low

    Animal-only data from one research group; the vascular finding rests on a single study.

    PMID 18642713 (hypoglycemia, capillary adhesion); PMID 16671579 (alloxan model, insulin biosynthesis); PMID 18225766 (pancreatic functional morphology)

  • Anti-apoptotic and geroprotective cellular effects

    Speculative

    Preliminary, based on one small study and review commentary, no lifespan or human data.

    PMID 21246099; PMID 31808038 (review)

Benefits(5)

  • Correction of impaired glucose tolerance in aging

    Goncharova et al. 2014 (Advances in Gerontology, PMID 25946840) — In aged female rhesus monkeys, 10-day intramuscular Pancragen (50 mcg/day) markedly increased glucose 'disappearance' rate and normalized plasma insulin and C-peptide dynamics in response to glucose administration. Effects partially remained 3 weeks after discontinuation. Goncharova et al. 2015 (Advances in Gerontology, PMID 28509500) — Comparative study in 9 elderly monkeys: Pancragen normalized insulin and C-peptide levels and was deemed effective and safe for correction of age-related endocrine pancreatic dysfunction, comparing favorably to glimepiride.

  • Reduction of fasting glucose and insulin resistance in elderly diabetic patients

    Korkushko et al. 2011 (Bulletin of Experimental Biology and Medicine, PMID 22448364) — Clinical study in 63 elderly subjects (33 with type 2 diabetes, 30 healthy controls). Pancragen significantly decreased fasting glucose levels, improved glucose tolerance test results, and reduced plasma insulin concentrations and insulin resistance index in diabetic patients. No improvements were observed in patients who did not receive Pancragen.

  • Stimulation of pancreatic cell differentiation and anti-aging gene expression

    Khavinson et al. 2013 (Bulletin of Experimental Biology and Medicine, PMID 23486591) — Pancragen stimulated expression of differentiation factors in both acinar (PDX1, PTF1A) and islet of Langerhans (PDX1, PAX6, PAX4, FOXA2, NKX2-2) cells in young and aged cultures. Expression of differentiation markers was reduced during aging, and Pancragen partially restored them. Khavinson et al. 2013 (Advances in Gerontology / Springer) — Pancragen increased MMP2, MMP9, serotonin, CD79a, Mcl-1, PCNA, and Ki67 expression while decreasing p53 in aged pancreatic cell cultures.

  • Hypoglycemic and endothelioprotective effects in experimental diabetes

    Khavinson et al. 2007 (Bulletin of Experimental Biology and Medicine, PMID 18642713) — In streptozotocin-induced diabetic rats, oral Pancragen produced a pronounced hypoglycemic effect during treatment. Intramuscular injection normalized adhesion of mesenteric capillary endothelium. The tetrapeptide demonstrated homeostatic and endothelioprotective effects in early-stage diabetes.

  • Anti-apoptotic and geroprotective cellular effects

    Khavinson et al. 2010 (Bulletin of Experimental Biology and Medicine, PMID 21246099) — Study of biological activity of the Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide showed decreased caspase-3 and cathepsin B activities (cellular aging biomarkers) following Pancragen exposure. In mature models, significant reduction in TNF-alpha and increase in IGF-I were observed — both critical markers for cellular aging and metabolic regulation.

Key studies(6)

  1. Prospects of using pancragen for correction of metabolic disorders in elderly people

    Clinical study (non-randomized, human)63 elderly subjects (33 with type 2 diabetes, 30 healthy controls)Not specified in abstract

    Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV

    Bulletin of Experimental Biology and Medicine

    2011

    Pancragen significantly decreased fasting glucose levels, improved glucose tolerance test results, and reduced plasma insulin concentrations and insulin resistance index in elderly patients with type 2 diabetes. No improvements were observed in patients who did not receive Pancragen. The study also noted that nocturnal melatonin production was reduced by 70% in diabetic patients, suggesting a link between pineal gland dysfunction and insulin resistance in aging.

  2. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys

    Experimental research (non-human primate)Aged female rhesus monkeys (exact n not reported in abstract)10 days treatment; follow-up at 3 weeks post-discontinuation

    Goncharova ND, Ivanova LG, Oganian TE, Vengerin AA, Khavinson VKh

    Advances in Gerontology

    2014

    Pancragen (50 mcg/animal/day, intramuscularly for 10 days) markedly increased glucose 'disappearance' rate and normalized plasma insulin and C-peptide dynamics in response to glucose administration in aged monkeys. Benefits partially remained 3 weeks after discontinuation, suggesting sustained effects. Concluded that Pancragen represents a promising factor for restoring age-related endocrine dysfunction.

  3. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys

    Comparative experimental study (non-human primate)9 elderly female rhesus monkeys (20-25 years old); 5 Pancragen, 4 glimepiride10 days treatment

    Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VKh

    Advances in Gerontology

    2015

    Both Pancragen and glimepiride reduced basal blood glucose. However, Pancragen normalized insulin and C-peptide levels, suggesting a recovering effect on disturbed glucose tolerance, while glimepiride produced a more expressed but delayed hypoglycemic effect without comparable insulin regulation. Pancragen was deemed effective and safe for correction of age-related endocrine pancreatic imbalance.

  4. Effects of pancragen on the differentiation of pancreatic cells during their ageing

    In vitro experimental studyHuman pancreatic cell cultures (young and aged)Cell culture experiment

    Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI

    Bulletin of Experimental Biology and Medicine

    2013

    Expression of differentiation markers was reduced during aging of pancreatic cells. Pancragen stimulated expression of differentiation factors in both acinar (PDX1, PTF1A) and islet of Langerhans (PDX1, PAX6, PAX4, FOXA2, NKX2-2) cells across young and aged cultures. The mechanism involves transcription factors regulating pancreatic cell differentiation, positioning Pancragen as a potential approach for diabetes and pancreatitis management.

  5. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus

    Experimental animal study (rat)Wistar rats with streptozotocin-induced diabetesTreatment course (duration not specified in abstract)

    Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL

    Bulletin of Experimental Biology and Medicine

    2007

    Oral Pancragen produced a pronounced hypoglycemic effect during treatment in diabetic rats. Intramuscular injection normalized adhesion of mesenteric capillary endothelium but did not modify capillary permeability. The tetrapeptide demonstrated homeostatic and endothelioprotective effects in early-stage diabetes mellitus.

  6. Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA

    Bulletin of Experimental Biology and Medicine

    2010

    Evaluated the biological effects of the natural tetrapeptide on metabolic parameters characterizing apoptosis in development and in experimentally-induced diabetes. Decreased caspase-3 and cathepsin B activities (cellular aging biomarkers). In mature models, significant reduction in TNF-alpha and increase in IGF-I were observed.

What research suggests over time

  • Weeks 2-4

    Russian clinical use

    Russian protocols use 5-10 day pulsatile dosing courses; subjective metabolic improvements reported.

  • Months 2-3

    Russian observational (n=63)

    Korkushko 2011 included 33 people with type 2 diabetes and 30 healthy comparators; metabolic improvements were reported in the diabetes group.

  • Long-term

    Russian + preclinical

    Animal data shows pancreatic regeneration markers and glucose normalization comparable to glimepiride. No Western RCTs.

Regulation & availability

Why researchers look at it

In aged rhesus monkeys, treatment normalized insulin dynamics and improved glucose tolerance — with effects lasting 3 weeks after the last dose — and a human study in 33 elderly diabetic patients showed significant reductions in fasting blood sugar. All evidence originates from a single Russian research group with no independent replication, but if confirmed, Pancragen could represent a targeted approach to restoring age-related pancreatic decline.

Estimated cost
$30-80/mo oral capsules
FDA status
NOT FDA-APPROVED. Pancragen has never been submitted for FDA review and holds no IND (Investigational New Drug), NDA (New Drug Application), or BLA (Biologics License Application) with the US Food and Drug Administration. It is not listed in the FDA Orange Book or the National Drug Code (NDC) directory. Pancragen is not recognized as a drug, biologic, or approved dietary supplement by the FDA. In Russia, it is classified as a peptide food supplement (not a pharmaceutical) under regulatory oversight by the St. Petersburg Institute of Bioregulation and Gerontology. Six other Khavinson peptide bioregulators (Thymalin, Cortexin, Epithalamin, Samprost, Retinalamin, and Thymogen) have been authorized by the Russian Ministry of Health as pharmaceuticals, but Pancragen is not among them — it remains in the 'peptide food supplement' category.
WADA status
NOT SPECIFICALLY PROHIBITED. Pancragen (Lys-Glu-Asp-Trp) is not individually named on the WADA 2026 Prohibited List. It does not fall under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), as it is not a growth hormone releasing factor, EPO, or growth factor. It is a short tissue-specific bioregulatory peptide without known direct performance-enhancing properties relevant to athletic competition. However, WADA's prohibited list includes a catch-all provision for substances not specifically named that are 'not currently approved by any governmental regulatory health authority for human therapeutic use' — which could theoretically encompass Pancragen since it lacks FDA/EMA approval. Athletes should exercise caution and consult their national anti-doping organization or GlobalDRO.com for definitive guidance, as interpretations may vary.
Prescribability
Pancragen is not FDA-approved. A prescription alone does not establish eligibility to compound Pancragen, and no qualifying US bulk-compounding pathway was identified in the reviewed FDA materials. In Russia and some CIS countries, it is commercially available as a dietary supplement (classified as a peptide food supplement, not a pharmaceutical) produced by the St. Petersburg Institute of Bioregulation and Gerontology, sold in capsule form under the Pancragen brand.
Availability
Pancragen is not part of mainstream Western medicine. In Russia it is sold as Pancragen capsules produced by the St. Petersburg Institute of Bioregulation and Gerontology, classified as a peptide food supplement rather than a pharmaceutical. Some functional medicine and bioregulator-focused practitioners, particularly in Europe and Florida, use it in anti-aging programs. No prescription is technically required for the supplement form in most jurisdictions, but medical supervision is advisable. Pancragen is not available through US or EU pharmacies, not listed in any pharmacopeia outside Russia, and cannot be obtained through standard prescription channels.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(12)

  1. 1971
    Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
  2. 1992
    St. Petersburg Institute of Bioregulation and Gerontology is established as Khavinson's primary research center for peptide bioregulator development.
  3. 2000s
    Pancragen tetrapeptide (Lys-Glu-Asp-Trp) is identified and synthesized as the active sequence from bovine pancreatic tissue extracts at the St. Petersburg Institute.
  4. 2007
    Khavinson et al. publish first Pancragen animal study showing hypoglycemic and endothelioprotective effects in diabetic rats (PMID 18642713).
  5. 2010
    Khavinson et al. publish study of biological activity of the Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide, demonstrating anti-apoptotic effects (PMID 21246099).
  6. 2011
    Korkushko et al. publish a human metabolic study involving 63 older people, reporting improvements in the type 2 diabetes group (PMID 22448364).
  7. 2013-02
    Khavinson et al. publish in vitro study showing Pancragen stimulates pancreatic cell differentiation factor expression in young and aged cultures (PMID 23486591).
  8. 2013
    Khavinson et al. publish Springer study on tetrapeptide stimulating functional activity of pancreatic cells in aging, detailing molecular markers (MMP2, MMP9, p53, Mcl-1, PCNA, Ki67).
  9. 2014
    Goncharova et al. publish first non-human primate study demonstrating Pancragen normalizes endocrine pancreatic function in aged monkeys (PMID 25946840).
  10. 2015
    Goncharova et al. publish comparative study of Pancragen vs. glimepiride in aged rhesus monkeys showing favorable insulin normalization (PMID 28509500).
  11. 2020s
    Gains attention in Western longevity and biohacking communities.
  12. 2026-03
    Pancragen remains without FDA review or approval. No IND has been filed. Not included in any ongoing ClinicalTrials.gov registrations.

Sources & FAQs

Research sources(9)

Frequently asked questions(5)

What is the difference between Pancragen and Suprefort?

Both are Khavinson-class peptide bioregulators targeting the pancreas. Suprefort (also called A-1) is a natural peptide complex extracted from bovine pancreatic tissue and contains a mixture of short peptides. Pancragen is a synthesized (synthetic) single tetrapeptide (Lys-Glu-Asp-Trp) that was identified as the active sequence from the natural extract. Pancragen is considered the more refined, standardized version with a defined molecular composition, while Suprefort is a crude tissue extract. In Khavinson's classification system, Suprefort is a 'Cytomaxes' (natural) and Pancragen is a 'Cytogens' (synthesized) product. Both target pancreatic function but Pancragen has more published research on its specific mechanism of action.

Is Pancragen safe? Are there side effects?

Published studies report a favorable safety profile with no significant toxic effects. The manufacturer states it does not cause allergic reactions or addiction. The primate study (Goncharova et al. 2015) explicitly concluded Pancragen is 'effective and safe for correction of age-related imbalance of endocrine pancreatic function.' However, safety data is limited to small studies from a single research group, with no large-scale safety trials, no long-term follow-up beyond a few weeks, and no independent safety monitoring. Contraindications listed by the manufacturer include individual component intolerance, pregnancy, and lactation.

Can Pancragen replace insulin or diabetes medications?

No. Pancragen is not a substitute for insulin or established diabetes medications. The research suggests it may help normalize pancreatic endocrine function and improve glucose tolerance in the context of age-related decline, but it has not been validated as a diabetes treatment in controlled clinical trials. The manufacturer recommends it as an adjunct to conventional medical treatment, not a replacement. Patients with diabetes should not alter their medication regimen based on Pancragen use without physician supervision.

How does Pancragen work at the molecular level?

Pancragen penetrates the cell nucleus and binds directly to DNA along the major groove, forming stable peptide-DNA complexes. This modulates gene transcription, particularly upregulating pancreatic differentiation transcription factors (PDX1, PTF1A, PAX6, PAX4, FOXA2, NKX2-2, NKX6.1). It also promotes DNA demethylation and histone remodeling at loci associated with insulin production and cell survival. Additionally, it increases expression of antiapoptotic proteins (Mcl-1) and proliferation markers (PCNA, Ki67) while decreasing proapoptotic protein p53. This epigenetic and transcriptional regulation is thought to restore functional capacity in aged pancreatic cells.

Is the research on Pancragen credible?

The research is published in legitimate peer-reviewed journals (Bulletin of Experimental Biology and Medicine, Advances in Gerontology) that are indexed in PubMed. However, all published studies originate from a single research group (Khavinson and collaborators), sample sizes are small, and no independent replication has been published by Western or international research groups. The human study was not a randomized, double-blind, placebo-controlled trial. While the findings are internally consistent across cell culture, rodent, primate, and human studies, independent validation would significantly strengthen the evidence base.